FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917151908> ?p ?o ?g. }

• W2917151908 endingPage "e000798" @default.
• W2917151908 startingPage "e000798" @default.
• W2917151908 abstract "Objective To compare efficacy and safety of subcutaneous sarilumab 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus other targeted DMARDs+csDMARDs and placebo+csDMARDs, in inadequate responders to csDMARDs (csDMARD-IR) or tumour necrosis factor α inhibitors (TNFi-IR). Methods Systematic literature review and network meta-analyses (NMA) conducted on 24 week efficacy and safety outcomes: Health Assessment Questionnaire Disability Index, modified total sharp score (mTSS, including 52 weeks), American College of Rheumatology (ACR) 20/50/70, European League Against Rheumatism Disease Activity Score 28-joint count erythrocyte sedimentation rate (DAS28)<2.6; serious infections/serious adverse events (including 52 weeks). Results 53 trials were selected for NMA. csDMARD-IR : Sarilumab 200 mg+csDMARDs and 150 mg+csDMARDs were superior versus placebo+csDMARDs on all outcomes. Against most targeted DMARDs, sarilumab 200 mg showed no statistically significant differences, except superiority to baricitinib 2 mg, tofacitinib and certolizumab on 24 week mTSS. Sarilumab 150 mg was similar to all targeted DMARDs. TNFi-IR: Sarilumab 200 mg was similar to abatacept, golimumab, tocilizumab 4 mg and 8 mg/kg intravenously and rituximab on ACR20/50/70, superior to baricitinib 2 mg on ACR50 and DAS28<2.6 and to abatacept, golimumab, tocilizumab 4 mg/kg intravenously and rituximab on DAS28<2.6. Sarilumab 150 mg was similar to targeted DMARDs but superior to baricitinib 2 mg and rituximab on DAS28<2.6 and inferior to tocilizumab 8 mg on ACR20 and DAS28<2.6. Serious adverse events, including serious infections, appeared similar for sarilumab versus comparators. Conclusions Results suggest that in csDMARD-IR and TNFi-IR (a smaller network), sarilumab+csDMARD had superior efficacy and similar safety versus placebo+csDMARDs and at least similar efficacy and safety versus other targeted DMARDs+csDMARDs." @default.
• W2917151908 created "2019-03-02" @default.
• W2917151908 creator A5004560391 @default.
• W2917151908 creator A5016395117 @default.
• W2917151908 creator A5029781530 @default.
• W2917151908 creator A5031103837 @default.
• W2917151908 creator A5038109838 @default.
• W2917151908 creator A5051493673 @default.
• W2917151908 creator A5057954505 @default.
• W2917151908 creator A5069919512 @default.
• W2917151908 creator A5083583562 @default.
• W2917151908 creator A5090085189 @default.
• W2917151908 date "2019-02-01" @default.
• W2917151908 modified "2023-10-16" @default.
• W2917151908 title "Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses" @default.
• W2917151908 cites W1524379422 @default.
• W2917151908 cites W1544512016 @default.
• W2917151908 cites W1586828706 @default.
• W2917151908 cites W1617328014 @default.
• W2917151908 cites W1967385770 @default.
• W2917151908 cites W1974402687 @default.
• W2917151908 cites W1986376914 @default.
• W2917151908 cites W2005947177 @default.
• W2917151908 cites W2009298607 @default.
• W2917151908 cites W2022144190 @default.
• W2917151908 cites W2031494385 @default.
• W2917151908 cites W2046628605 @default.
• W2917151908 cites W2057765075 @default.
• W2917151908 cites W2060992747 @default.
• W2917151908 cites W2063738853 @default.
• W2917151908 cites W2069302785 @default.
• W2917151908 cites W2095714646 @default.
• W2917151908 cites W2097997129 @default.
• W2917151908 cites W2099880429 @default.
• W2917151908 cites W2102207725 @default.
• W2917151908 cites W2113144077 @default.
• W2917151908 cites W2120393706 @default.
• W2917151908 cites W2125776201 @default.
• W2917151908 cites W2127622911 @default.
• W2917151908 cites W2131701504 @default.
• W2917151908 cites W2139323151 @default.
• W2917151908 cites W2142004396 @default.
• W2917151908 cites W2143502358 @default.
• W2917151908 cites W2143972196 @default.
• W2917151908 cites W2169853546 @default.
• W2917151908 cites W2218724983 @default.
• W2917151908 cites W2319057316 @default.
• W2917151908 cites W2325624679 @default.
• W2917151908 cites W2330706340 @default.
• W2917151908 cites W2415231638 @default.
• W2917151908 cites W2513662764 @default.
• W2917151908 cites W2549509332 @default.
• W2917151908 cites W2557016092 @default.
• W2917151908 cites W2588044396 @default.
• W2917151908 cites W2616379431 @default.
• W2917151908 doi "https://doi.org/10.1136/rmdopen-2018-000798" @default.
• W2917151908 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6397432" @default.
• W2917151908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30886733" @default.
• W2917151908 hasPublicationYear "2019" @default.
• W2917151908 type Work @default.
• W2917151908 sameAs 2917151908 @default.
• W2917151908 citedByCount "12" @default.
• W2917151908 countsByYear W29171519082019 @default.
• W2917151908 countsByYear W29171519082020 @default.
• W2917151908 countsByYear W29171519082021 @default.
• W2917151908 countsByYear W29171519082022 @default.
• W2917151908 crossrefType "journal-article" @default.
• W2917151908 hasAuthorship W2917151908A5004560391 @default.
• W2917151908 hasAuthorship W2917151908A5016395117 @default.
• W2917151908 hasAuthorship W2917151908A5029781530 @default.
• W2917151908 hasAuthorship W2917151908A5031103837 @default.
• W2917151908 hasAuthorship W2917151908A5038109838 @default.
• W2917151908 hasAuthorship W2917151908A5051493673 @default.
• W2917151908 hasAuthorship W2917151908A5057954505 @default.
• W2917151908 hasAuthorship W2917151908A5069919512 @default.
• W2917151908 hasAuthorship W2917151908A5083583562 @default.
• W2917151908 hasAuthorship W2917151908A5090085189 @default.
• W2917151908 hasBestOaLocation W29171519081 @default.
• W2917151908 hasConcept C126322002 @default.
• W2917151908 hasConcept C142724271 @default.
• W2917151908 hasConcept C197934379 @default.
• W2917151908 hasConcept C204787440 @default.
• W2917151908 hasConcept C27081682 @default.
• W2917151908 hasConcept C2777178219 @default.
• W2917151908 hasConcept C2777226972 @default.
• W2917151908 hasConcept C2777575956 @default.
• W2917151908 hasConcept C2778886723 @default.
• W2917151908 hasConcept C2779338263 @default.
• W2917151908 hasConcept C2779605438 @default.
• W2917151908 hasConcept C2780653079 @default.
• W2917151908 hasConcept C2781290027 @default.
• W2917151908 hasConcept C71924100 @default.
• W2917151908 hasConceptScore W2917151908C126322002 @default.
• W2917151908 hasConceptScore W2917151908C142724271 @default.
• W2917151908 hasConceptScore W2917151908C197934379 @default.
• W2917151908 hasConceptScore W2917151908C204787440 @default.
• W2917151908 hasConceptScore W2917151908C27081682 @default.
• W2917151908 hasConceptScore W2917151908C2777178219 @default.

• next